Antegren BLA Submission For Multiple Sclerosis Could See Approval By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec and Elan are requesting priority review for the MS submission. Companies are also seeking accelerated approval; BLA is based on one-year data from ongoing AFFIRM and SENTINEL trials.